<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287219</url>
  </required_header>
  <id_info>
    <org_study_id>CB-17-01/03</org_study_id>
    <nct_id>NCT03287219</nct_id>
  </id_info>
  <brief_title>Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX</brief_title>
  <acronym>CRO-11-108</acronym>
  <official_title>Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX® Modified Release Tablets Administered to Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cosmo Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cosmo Pharmaceuticals NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after&#xD;
      total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various&#xD;
      reasons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after&#xD;
      total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various&#xD;
      reasons.&#xD;
&#xD;
      Primary end-point(s):&#xD;
&#xD;
      To evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral&#xD;
      doses of 150 or 200 mg.&#xD;
&#xD;
      Secondary end-point(s):&#xD;
&#xD;
      Bowel cleansing quality evaluated according to the validated Boston Bowel Preparation Scale&#xD;
      (BBPS) after intake of 150 or 200 mg of Methylene Blue MMX® tablets during the intake of the&#xD;
      bowel cleansing preparation.&#xD;
&#xD;
      To collect data about safety and tolerability of Methylene Blue MMX® tablets after&#xD;
      administration of single oral doses of 150 or 200 mg.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Open label, staining efficacy exploratory study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2011</start_date>
  <completion_date type="Actual">January 16, 2012</completion_date>
  <primary_completion_date type="Actual">January 16, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, staining efficacy exploratory study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None. Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Mucosal Staining Efficacy</measure>
    <time_frame>One day- mucosal staining efficacy is assessed during the colonoscopy procedure</time_frame>
    <description>Mucosal staining efficacy of Methylene Blue MMX tablets after total oral doses of 150 or 200 mg.&#xD;
Methylene blue staining efficacy was assessed by scoring the observed percentage of staining as reported below for each colon region (AC, TC, DC, RES) 0 - no staining&#xD;
- traces (poor traces in colon mucosa)&#xD;
- detectable (at least the 25% of colon mucosa is stained)&#xD;
- acceptable (at least the 50% of colon mucosa is stained)&#xD;
- good (at least the 75% of colon mucosa is stained)&#xD;
- over stained ( the 100% of the colon mucosa is over stained) After scoring (SC) separately each colonic segment, the total staining score (TSC) was also calculated and the number of regions with an SC&gt;2 (NSA) was determined.&#xD;
For each patient, the best effective TSC was set at 16, when SC=4 was detected in all 4 regions. SC=5 detected in any region and TSC&gt;16, both denoting an overstaining of the mucosa, were defined as suboptimal results in colon staining.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Blood Pressure)</measure>
    <time_frame>until study completion (until 2 days after dose)</time_frame>
    <description>safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Methylene Blue MMX as Determined by AEs</measure>
    <time_frame>Until study completion (until 2 days after dose)</time_frame>
    <description>Safety and tolerability of Methylene Blue MMX® tablets after administration of total oral doses of 150 or 200 mg.AEs were assessed throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Methylene Blue MMX as Determined by Heart Rate</measure>
    <time_frame>until study completion (until 2 days after dose)</time_frame>
    <description>incidence of treatment emergent by measurement of vital signs (heart rate) to determine Safety and Tolerability of Methylene Blue MMX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Oxygen Saturation in Peripheral Blood)</measure>
    <time_frame>until study completion (until 2 days after dose)</time_frame>
    <description>safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (Oxygen Saturation in peripheral blood)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Methylene Blue MMX as Determined Body Weight.</measure>
    <time_frame>until study completion (until 2 days after dose)</time_frame>
    <description>safety and tolerability of Methylene Blue MMX in relation to incidence of treatment emergent by body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Cleansing Quality-Boston Bowel Preparation Score</measure>
    <time_frame>One day- bowel cleansing quality is assessed during the colonoscopy procedure</time_frame>
    <description>Bowel cleansing quality evaluated according to the validated Boston Bowel Preparation Scale (BBPS).&#xD;
Colon was divided into 4 target regions: ascending colon (AC), transverse colon (TC), descending colon (DC) and rectosigmoid (RES). Methylene blue staining efficacy was assessed scoring the observed staining percentage as reported below for each colon region:&#xD;
0 - no staining&#xD;
- traces (poor traces in colon mucosa)&#xD;
- detectable (at least the 25% of colon mucosa is stained)&#xD;
- acceptable (at least the 50% of colon mucosa is stained)&#xD;
- good (at least the 75% of colon mucosa is stained)&#xD;
- over stained ( the 100% of the colon mucosa is over stained)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Colon Staining in Preparation for Colonoscopy</condition>
  <arm_group>
    <arm_group_label>150 mg Methylene Blue-MMX tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Methylene Blue-MMX tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue MMX 25 mg modified release tablets</intervention_name>
    <description>Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.</description>
    <arm_group_label>150 mg Methylene Blue-MMX tablets</arm_group_label>
    <arm_group_label>200 mg Methylene Blue-MMX tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sex: males and females;&#xD;
&#xD;
          2. Age:18 to 70 years;&#xD;
&#xD;
          3. Colonoscopy: out-patients with indication for colonoscopy including faecal occult&#xD;
             blood test positive colorectal cancer screening, polypectomy follow-up and&#xD;
             inflammatory bowel disease check;&#xD;
&#xD;
          4. Contraception: either sterile subjects or subjects practising at least one reliable&#xD;
             methods of contraception or in post-menopausal status for at least 1 year;&#xD;
&#xD;
          5. Informed Consent: signed written informed consent prior to inclusion in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy: pregnant or lactating women or at a risk of becoming pregnant;&#xD;
&#xD;
          2. Allergy: known or suspected hypersensitivity to the active principle and/or&#xD;
             formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in&#xD;
             general;&#xD;
&#xD;
          3. Diseases: known or suspected gastrointestinal obstruction or perforation, toxic&#xD;
             megacolon, major colonic resection, inflammatory bowel diseases in active phase,&#xD;
             severe diverticulosis with diverticulitis, heart failure (Class III or IV), serious&#xD;
             cardiovascular disease, severe liver failure, end-stage renal insufficiency, any other&#xD;
             relevant disease that might interfere with the aim of the study.&#xD;
&#xD;
          4. Comprehension: inability to comprehend the full nature and purpose of the study and&#xD;
             unwillingness to co-operate with the Investigator and to comply with the requirements&#xD;
             of the entire study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <results_first_submitted>December 1, 2017</results_first_submitted>
  <results_first_submitted_qc>January 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>150 mg Methylene Blue-MMX Tablets</title>
          <description>take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg&#xD;
Methylene Blue MMX 25 mg modified release tablets: Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.</description>
        </group>
        <group group_id="P2">
          <title>200 mg Methylene Blue-MMX Tablets</title>
          <description>take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg&#xD;
Methylene Blue MMX 25 mg modified release tablets: Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methylene Blue MMX 150mg</title>
          <description>Patients under going Colonoscpy taking Methylene Blue-MMX tablets equivalent to 150 mg</description>
        </group>
        <group group_id="B2">
          <title>Methylene Blue MMX 200mg</title>
          <description>Patients under going Colonoscpy taking Methylene Blue-MMX tablets equivalent to 200 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="11.0"/>
                    <measurement group_id="B2" value="55.6" spread="11.2"/>
                    <measurement group_id="B3" value="54.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimetres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.5" spread="8.4"/>
                    <measurement group_id="B2" value="168.5" spread="8.7"/>
                    <measurement group_id="B3" value="167.4" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="13.3"/>
                    <measurement group_id="B2" value="70.6" spread="14.2"/>
                    <measurement group_id="B3" value="69" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Mucosal Staining Efficacy</title>
        <description>Mucosal staining efficacy of Methylene Blue MMX tablets after total oral doses of 150 or 200 mg.&#xD;
Methylene blue staining efficacy was assessed by scoring the observed percentage of staining as reported below for each colon region (AC, TC, DC, RES) 0 - no staining&#xD;
- traces (poor traces in colon mucosa)&#xD;
- detectable (at least the 25% of colon mucosa is stained)&#xD;
- acceptable (at least the 50% of colon mucosa is stained)&#xD;
- good (at least the 75% of colon mucosa is stained)&#xD;
- over stained ( the 100% of the colon mucosa is over stained) After scoring (SC) separately each colonic segment, the total staining score (TSC) was also calculated and the number of regions with an SC&gt;2 (NSA) was determined.&#xD;
For each patient, the best effective TSC was set at 16, when SC=4 was detected in all 4 regions. SC=5 detected in any region and TSC&gt;16, both denoting an overstaining of the mucosa, were defined as suboptimal results in colon staining.</description>
        <time_frame>One day- mucosal staining efficacy is assessed during the colonoscopy procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A (Dose:150mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation:&#xD;
At the beginning - 2 After the 1st L - 2 After the 2nd L - 2 After the 3rd L - 0 At the end - 0</description>
          </group>
          <group group_id="O2">
            <title>B (Dose:150mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation:&#xD;
At the beginning - 6 After the 1st L - 0 After the 2nd L- 0 After the 3rd L- 0 At the end- 0</description>
          </group>
          <group group_id="O3">
            <title>C (Dose:150mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation:&#xD;
At the beginning - 0 After the 1st L - 0 After the 2nd L - 0 After the 3rd L - 0 At the end - 6</description>
          </group>
          <group group_id="O4">
            <title>D (Dose:200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation At the beginning -4 After the 1st L-2 After the 2nd L-2 After the 3rd L-0 At the end-0</description>
          </group>
          <group group_id="O5">
            <title>E (Dose:200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation At the beginning -0 After the 1st L-0 After the 2nd L-0 After the 3rd L-0 At the end-8</description>
          </group>
          <group group_id="O6">
            <title>F (Dose:200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation At the beginning -2 After the 1st L-2 After the 2nd L-2 After the 3rd L-0 At the end-2</description>
          </group>
          <group group_id="O7">
            <title>G (Dose 200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation At the beginning -4 After the 1st L-2 After the 2nd L-2 After the 3rd L-0 At the end-0</description>
          </group>
          <group group_id="O8">
            <title>H (Dose:200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation At the beginning -0 After the 1st L-0 After the 2nd L-0 After the 3rd L-4 At the end-4</description>
          </group>
          <group group_id="O9">
            <title>I (Dose:200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation At the beginning -0 After the 1st L-0 After the 2nd L-4 After the 3rd L-4 At the end-0</description>
          </group>
          <group group_id="O10">
            <title>J (Dose:200mg)</title>
            <description>Number of tablets taken in relation to the intake of the bowel cleansing preparation:&#xD;
At the beginning - 0 After the 1st L - 0 After the 2nd L - 2 After the 3rd L - 3 At the end - 3</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Mucosal Staining Efficacy</title>
          <description>Mucosal staining efficacy of Methylene Blue MMX tablets after total oral doses of 150 or 200 mg.&#xD;
Methylene blue staining efficacy was assessed by scoring the observed percentage of staining as reported below for each colon region (AC, TC, DC, RES) 0 - no staining&#xD;
- traces (poor traces in colon mucosa)&#xD;
- detectable (at least the 25% of colon mucosa is stained)&#xD;
- acceptable (at least the 50% of colon mucosa is stained)&#xD;
- good (at least the 75% of colon mucosa is stained)&#xD;
- over stained ( the 100% of the colon mucosa is over stained) After scoring (SC) separately each colonic segment, the total staining score (TSC) was also calculated and the number of regions with an SC&gt;2 (NSA) was determined.&#xD;
For each patient, the best effective TSC was set at 16, when SC=4 was detected in all 4 regions. SC=5 detected in any region and TSC&gt;16, both denoting an overstaining of the mucosa, were defined as suboptimal results in colon staining.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="4.0"/>
                    <measurement group_id="O2" value="2.3" spread="2.4"/>
                    <measurement group_id="O3" value="8.1" spread="3.6"/>
                    <measurement group_id="O4" value="7.0" spread="5.0"/>
                    <measurement group_id="O5" value="9.8" spread="4.1"/>
                    <measurement group_id="O6" value="10.5" spread="4.1"/>
                    <measurement group_id="O7" value="10.5" spread="7.8"/>
                    <measurement group_id="O8" value="10.0" spread="3.2"/>
                    <measurement group_id="O9" value="11.4" spread="3.8"/>
                    <measurement group_id="O10" value="11.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Blood Pressure)</title>
        <description>safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (blood pressure)</description>
        <time_frame>until study completion (until 2 days after dose)</time_frame>
        <population>Safety population: the safety population was defined as all enrolled subjects who received at least one dose of the study drug. This population was used for safety evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Pre Colonoscopy - 150mg Dose</title>
            <description>Vital Signs - safety Population -- 150mg dose</description>
          </group>
          <group group_id="O2">
            <title>Pre Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population- 200mg dose</description>
          </group>
          <group group_id="O3">
            <title>During Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population- 150mg dose</description>
          </group>
          <group group_id="O4">
            <title>During Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population- 200mg dose</description>
          </group>
          <group group_id="O5">
            <title>Post Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population- 150mg dose</description>
          </group>
          <group group_id="O6">
            <title>Post Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population- 200mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Blood Pressure)</title>
          <description>safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (blood pressure)</description>
          <population>Safety population: the safety population was defined as all enrolled subjects who received at least one dose of the study drug. This population was used for safety evaluation</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure (mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.6" spread="14.6"/>
                    <measurement group_id="O2" value="124.3" spread="17.7"/>
                    <measurement group_id="O3" value="122.6" spread="14.6"/>
                    <measurement group_id="O4" value="124.3" spread="17.7"/>
                    <measurement group_id="O5" value="122.7" spread="14.5"/>
                    <measurement group_id="O6" value="124.2" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure(mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="8.1"/>
                    <measurement group_id="O2" value="74.0" spread="11.9"/>
                    <measurement group_id="O3" value="74.9" spread="8.2"/>
                    <measurement group_id="O4" value="74.0" spread="11.9"/>
                    <measurement group_id="O5" value="75" spread="8.2"/>
                    <measurement group_id="O6" value="74.0" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Methylene Blue MMX as Determined by AEs</title>
        <description>Safety and tolerability of Methylene Blue MMX® tablets after administration of total oral doses of 150 or 200 mg.AEs were assessed throughout the study.</description>
        <time_frame>Until study completion (until 2 days after dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre Colonoscopy - 150mg Dose</title>
            <description>Vital Signs - safety Population -- 150mg dose</description>
          </group>
          <group group_id="O2">
            <title>Pre Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population- 200mg dose</description>
          </group>
          <group group_id="O3">
            <title>During Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population- 150mg dose</description>
          </group>
          <group group_id="O4">
            <title>During Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population- 200mg dose</description>
          </group>
          <group group_id="O5">
            <title>Post Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population- 150mg dose</description>
          </group>
          <group group_id="O6">
            <title>Post Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population- 200mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Methylene Blue MMX as Determined by AEs</title>
          <description>Safety and tolerability of Methylene Blue MMX® tablets after administration of total oral doses of 150 or 200 mg.AEs were assessed throughout the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Methylene Blue MMX as Determined by Heart Rate</title>
        <description>incidence of treatment emergent by measurement of vital signs (heart rate) to determine Safety and Tolerability of Methylene Blue MMX</description>
        <time_frame>until study completion (until 2 days after dose)</time_frame>
        <population>Safety population: the safety population was defined as all enrolled subjects who received at least one dose of the study drug. This population was used for safety evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Pre Colonoscopy - 150mg Dose</title>
            <description>Vital Signs - safety Population - 150mg dose</description>
          </group>
          <group group_id="O2">
            <title>Pre Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population - 200mg dose</description>
          </group>
          <group group_id="O3">
            <title>During Colonoscopy - 150mg Dose</title>
            <description>Vital Signs - safety Population - 150mg dose</description>
          </group>
          <group group_id="O4">
            <title>During Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population - 200mg dose</description>
          </group>
          <group group_id="O5">
            <title>Post Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population - 150mg dose</description>
          </group>
          <group group_id="O6">
            <title>Post Colonoscopy- 200mg Dose</title>
            <description>Vital Signs - safety Population - 200mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Methylene Blue MMX as Determined by Heart Rate</title>
          <description>incidence of treatment emergent by measurement of vital signs (heart rate) to determine Safety and Tolerability of Methylene Blue MMX</description>
          <population>Safety population: the safety population was defined as all enrolled subjects who received at least one dose of the study drug. This population was used for safety evaluation</population>
          <units>beats per minute (BPM)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="10.6"/>
                    <measurement group_id="O2" value="75.2" spread="15.1"/>
                    <measurement group_id="O3" value="74.3" spread="10.9"/>
                    <measurement group_id="O4" value="75.3" spread="15.1"/>
                    <measurement group_id="O5" value="74.2" spread="10.9"/>
                    <measurement group_id="O6" value="7.1" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Oxygen Saturation in Peripheral Blood)</title>
        <description>safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (Oxygen Saturation in peripheral blood)</description>
        <time_frame>until study completion (until 2 days after dose)</time_frame>
        <population>Safety population: the safety population was defined as all enrolled subjects who received at least one dose of the study drug. This population was used for safety evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Pre Colonoscopy - 150mg Dose</title>
            <description>Vital Signs - safety Population</description>
          </group>
          <group group_id="O2">
            <title>Pre Colonoscopy- 200mg Dose</title>
          </group>
          <group group_id="O3">
            <title>During Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population</description>
          </group>
          <group group_id="O4">
            <title>During Colonoscopy- 200mg Dose</title>
          </group>
          <group group_id="O5">
            <title>Post Colonoscopy- 150mg Dose</title>
            <description>Vital Signs - safety Population</description>
          </group>
          <group group_id="O6">
            <title>Post Colonoscopy- 200mg Dose</title>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Methylene Blue MMX as Determined by Vital Signs (Oxygen Saturation in Peripheral Blood)</title>
          <description>safety and tolerability of Methylene Blue MMX reviewed by incidence of treatment emergent by measurement of vital signs (Oxygen Saturation in peripheral blood)</description>
          <population>Safety population: the safety population was defined as all enrolled subjects who received at least one dose of the study drug. This population was used for safety evaluation</population>
          <units>percentage of saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" spread="1.8"/>
                    <measurement group_id="O2" value="98.7" spread="6.6"/>
                    <measurement group_id="O3" value="98.4" spread="1.8"/>
                    <measurement group_id="O4" value="98.8" spread="6.5"/>
                    <measurement group_id="O5" value="98.4" spread="1.8"/>
                    <measurement group_id="O6" value="98.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Methylene Blue MMX as Determined Body Weight.</title>
        <description>safety and tolerability of Methylene Blue MMX in relation to incidence of treatment emergent by body weight.</description>
        <time_frame>until study completion (until 2 days after dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visit 1-Screening 150mL</title>
            <description>Safety Population 150mL Dose</description>
          </group>
          <group group_id="O2">
            <title>Visit 1-Screening 200mL</title>
            <description>Safety Population 200mL Dose</description>
          </group>
          <group group_id="O3">
            <title>Visit 2-Final 150mL</title>
            <description>Safety Population 150mL Dose</description>
          </group>
          <group group_id="O4">
            <title>Visit 2-Final 200mL</title>
            <description>Safety Population 200mL Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Methylene Blue MMX as Determined Body Weight.</title>
          <description>safety and tolerability of Methylene Blue MMX in relation to incidence of treatment emergent by body weight.</description>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="13.0"/>
                    <measurement group_id="O2" value="71.3" spread="15.9"/>
                    <measurement group_id="O3" value="67.4" spread="13.0"/>
                    <measurement group_id="O4" value="71.2" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Cleansing Quality-Boston Bowel Preparation Score</title>
        <description>Bowel cleansing quality evaluated according to the validated Boston Bowel Preparation Scale (BBPS).&#xD;
Colon was divided into 4 target regions: ascending colon (AC), transverse colon (TC), descending colon (DC) and rectosigmoid (RES). Methylene blue staining efficacy was assessed scoring the observed staining percentage as reported below for each colon region:&#xD;
0 - no staining&#xD;
- traces (poor traces in colon mucosa)&#xD;
- detectable (at least the 25% of colon mucosa is stained)&#xD;
- acceptable (at least the 50% of colon mucosa is stained)&#xD;
- good (at least the 75% of colon mucosa is stained)&#xD;
- over stained ( the 100% of the colon mucosa is over stained)</description>
        <time_frame>One day- bowel cleansing quality is assessed during the colonoscopy procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg Methylene Blue-MMX Tablets</title>
            <description>take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg&#xD;
Methylene Blue MMX 25 mg modified release tablets: Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Methylene Blue-MMX Tablets</title>
            <description>take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg&#xD;
Methylene Blue MMX 25 mg modified release tablets: Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.</description>
          </group>
          <group group_id="O3">
            <title>Overall</title>
            <description>Overall Colon cleansing score</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Cleansing Quality-Boston Bowel Preparation Score</title>
          <description>Bowel cleansing quality evaluated according to the validated Boston Bowel Preparation Scale (BBPS).&#xD;
Colon was divided into 4 target regions: ascending colon (AC), transverse colon (TC), descending colon (DC) and rectosigmoid (RES). Methylene blue staining efficacy was assessed scoring the observed staining percentage as reported below for each colon region:&#xD;
0 - no staining&#xD;
- traces (poor traces in colon mucosa)&#xD;
- detectable (at least the 25% of colon mucosa is stained)&#xD;
- acceptable (at least the 50% of colon mucosa is stained)&#xD;
- good (at least the 75% of colon mucosa is stained)&#xD;
- over stained ( the 100% of the colon mucosa is over stained)</description>
          <units>Colon cleansing score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.7"/>
                    <measurement group_id="O2" value="5.4" spread="1.1"/>
                    <measurement group_id="O3" value="5.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AEs Methylene Blue-MMX Tablets Equivalent to 150 mg</title>
          <description>Patients under going Colonoscpy taking Methylene Blue MMX Dose 150mL</description>
        </group>
        <group group_id="E2">
          <title>AEs Methylene Blue-MMX Tablets Equivalent to 200 mg</title>
          <description>Patients under going Colonoscpy taking Methylene Blue MMX dose 200 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>R&amp;D Manager</name_or_title>
      <organization>Cosmo Technologies Ltd</organization>
      <email>rjones@cosmopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

